(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Cocoa Prices Undercut Amid the Prospects of Abundant Supplies - 2Manual for Instructive Application for Youngsters
- 3The Golden Globes gift bag has nearly $1 million worth of swag for some winners and presenters. What's in it?
- 4Catch the moon dancing with bright star Regulus tonight
- 5The most effective method to Pick A Trade-in vehicle Stage
- Climate leaders are talking about 'overshoot' into warming danger zone. Here's what it means
- 23 Most Amusing Messages At any point Sent Among Kids and Their Folks
- 6 Eyewear Brands Worth Purchasing
- Most loved Seared Chicken: Which Chain Rules?
- What's changing about healthcare in 2026 — Medicare, Medicaid, ACA, premiums, and enrollment deadlines
- Doritos and Cheetos debut 'NKD' options, without artificial colors or flavors
- Exploring the School Application Cycle: Understudy Bits of knowledge
- Firefighters rescue two Israelis trapped in vehicles on flooded roads in West Bank
- Native artists in Texas and Mexico shared their vision of the universe for 4,000 years, ancient murals suggest
